Your browser doesn't support javascript.
loading
Ferritin, inflammation, and iron deficiency in acute heart failure: evidence from the EDIFICA cohort.
Vasques-Nóvoa, Francisco; Pimentel, Maria João; Marques, Pedro; Vale, Catarina; Gomes, Filipa; Neves, João Sérgio; Barroso, Isaac; Guimarães, João Tiago; Bettencourt, Paulo; Leite-Moreira, Adelino F; Roncon-Albuquerque, Roberto; Almeida, Jorge; Ferreira, João Pedro; Friões, Fernando.
Affiliation
  • Vasques-Nóvoa F; Department of Internal Medicine, Centro Hospitalar Universitário de São João, Porto, Portugal. fvasquesnovoa@med.up.pt.
  • Pimentel MJ; Cardiovascular Research and Development Center (UnIC@RISE), Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Alameda Hernâni Monteiro, 4200-319, Porto, Portugal. fvasquesnovoa@med.up.pt.
  • Marques P; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal. fvasquesnovoa@med.up.pt.
  • Vale C; Cardiovascular Research and Development Center (UnIC@RISE), Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Alameda Hernâni Monteiro, 4200-319, Porto, Portugal.
  • Gomes F; Department of Internal Medicine, Centro Hospitalar Universitário de São João, Porto, Portugal.
  • Neves JS; Cardiovascular Research and Development Center (UnIC@RISE), Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Alameda Hernâni Monteiro, 4200-319, Porto, Portugal.
  • Barroso I; Department of Internal Medicine, Centro Hospitalar Universitário de São João, Porto, Portugal.
  • Guimarães JT; Cardiovascular Research and Development Center (UnIC@RISE), Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Alameda Hernâni Monteiro, 4200-319, Porto, Portugal.
  • Bettencourt P; Department of Internal Medicine, Centro Hospitalar Universitário de São João, Porto, Portugal.
  • Leite-Moreira AF; Cardiovascular Research and Development Center (UnIC@RISE), Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Alameda Hernâni Monteiro, 4200-319, Porto, Portugal.
  • Roncon-Albuquerque R; Cardiovascular Research and Development Center (UnIC@RISE), Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Alameda Hernâni Monteiro, 4200-319, Porto, Portugal.
  • Almeida J; Department of Endocrinology, Centro Hospitalar Universitário de São João, Porto, Portugal.
  • Ferreira JP; Department of Clinical Pathology, Centro Hospitalar Universitário de São João, Porto, Portugal.
  • Friões F; Department of Clinical Pathology, Centro Hospitalar Universitário de São João, Porto, Portugal.
Clin Res Cardiol ; 2024 Sep 19.
Article in En | MEDLINE | ID: mdl-39297941
ABSTRACT

BACKGROUND:

Ferritin is commonly used to evaluate iron stores and guide therapeutic decisions regarding intravenous iron supplementation. However, in the context of AHF, inflammation-driven upregulation of ferritin might disrupt its correlation with iron stores, restricting iron bioavailability and potentially amplifying the inflammatory response.

AIM:

This study aims to assess the clinical and prognostic associations of ferritin levels in an AHF cohort and to determine whether the prognostic value of ferritin is influenced by the presence of infection, inflammatory activation, and other markers of iron deficiency.

METHODS:

The association between ferritin and clinical outcomes (180 days) in AHF was evaluated in a cohort of 526 patients from the EDIFICA registry.

RESULTS:

The median ferritin plasma concentration at admission was 180 pg/mL. Patients with higher ferritin levels at admission were predominantly men, exhibiting a high prevalence of chronic kidney disease and alcohol consumption, and presenting with lower blood pressure and a higher incidence of clinical infection. Higher ferritin levels were associated with increased risk of the composite of heart failure hospitalization or cardiovascular death (Tertile 2 HR 1.75; 95% CI 1.10-2.79; p = 0.017; Tertile 3 HR 1.79; 95% CI 1.08-2.97; p = 0.025), independently of classical HF prognostic factors, inflammatory and iron-related markers. No significant associations were found between admission serum iron or transferrin saturation tertiles, iron status categories, or guideline-defined iron deficiency (ID) criteria and the primary composite outcome. However, at discharge, patients who met the criteria for defective iron utilization, low iron storage, or guideline-defined ID had a lower risk of the composite endpoint compared to those with normal iron utilization or who did not meet the guideline-defined ID criteria, respectively.

CONCLUSIONS:

Elevated ferritin levels are independently associated with poor prognosis in AHF. Low ferritin levels are associated with a favorable outcome and do not carry significant value in identifying ID in this population.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Res Cardiol Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Res Cardiol Year: 2024 Document type: Article